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 ABSTRACT 
 
The goal of this review was to explore the structure and function of 
neuromelanin and the role it plays in homeostasis and neurodegeneration by 
consolidating and synthesizing published scientific information in this area.  This 
paper gives an overview of both healthy neuromelanin function and pathological 
neurodegenerative processes.  Neuromelanin can play both a protective role and/or a 
damaging neurotoxic role.  This review explores and highlights in more detail the 
roles, structure and function of neuromelanin and possible ways to alleviate the 
damaging effects. 
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Introduction 
 
Neuromelanin (NM) is a dark polymer pigment produced in certain 
catecholaminergic neurons and appears in greatest quantities in the human brain.  
Interest in the pigment is on the upswing in recent years due to a hypothesized link 
between NM and the especially vulnerable neuromelanin containing neurons to cell 
degeneration in Parkinson’s disease (PD).1,2  Unlike peripheral melanins, which can be 
transferred to other cell types and produced in melanocytes, neuromelanin granules are 
believed to be stored in the cell in which it was produced.1,2,3  Neuromelanin is more 
heterogenous in appearance compared to peripheral melanins and is traditionally 
thought to result from non-enzymatic synthesis with no known pathway for 
catabolism.  Neuromelanin is believed to function in vivo to attenuate damaging 
stimuli effects with the possibility of interacting with transition metals, especially iron, 
and to mediate intracellular oxidative mechanisms.  Neuromelanin in PD brains 
suggest this function may be compromised, rendering pigmented neurons vulnerable 
to oxidative damage.1,2,3 Neuromelanin binds iron and plays a protective and/or 
damaging role in brain chemistry.  The role is dependent on the amount of bound iron.  
Dopamine is oxidized by iron and forms a quinone byproduct.  These byproducts can 
initiate toxic pathways leading to neurodegenerative cell death.4 
In recent years, more neuromelanin research is being conducted.  Areas include 
Parkinson’s Disease and other neurodegenerative diseases.  Neuromelanin has been 
somewhat of a mystery to the science community.  Although we have learned much 
about the synthesis and some of its functions, we still have much to learn about 
neuromelanin dysfunction and how it effects homeostasis.  In this review, we will be 
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looking at neuromelanin mechanisms and dysfunction as well as the role it plays in 
neurodegenerative disorders. 
Types of Neuromelanin and Distribution 
 Melanin in the brain has a similar appearance and structure to cutaneous 
melanins.  Due to their base molecular structures, melanins are classified into four 
groups, which include eumelanin, pheomelanin, neuromelanin, and allomelanin.  
Neuromelanin is thought to be related to melanins outside of the central nervous 
system and to be a combination of eumelanin and pheomelanin.1 NM is found in two 
types of catecholamine synthesis cells, noradrenaline and dopamine.  NM in these 
cells is likely composed of various neurotransmitters produced in the specified 
neuronal cells, although this has not been proven due to the small number of cells that 
produce these neurotransmitters.  It is thought that NM is formed by oxidative 
polymerization of dopamine and noradrenaline with possible involvement of cysteinyl 
derivatives.  Neurons that produce NM are primarily found in the brainstem, the 
brainstem pigment in the midbrain and pons, some in the hypothalamus, medulla 
oblongata, the cerebellum near the fourth ventricle, and the spinal sympathetic 
ganglia.  Except for the spinal sympathetic ganglia, these regions are involved in 
conscious perception, movement, emotion and memory.  The group in the midbrain 
and hypothalamus contain dopamine, those in the pons contain noradrenaline, while 
those in the medulla oblongata contain noradrenaline and adrenaline.1 Sixty-five 
percent of noradrenaline neurons contain NM, which suggests synthesis and use of 
noradrenaline.  Noradrenergic NM containing neurons are important for autonomic 
control of cardiac and respiratory integration and regulation of hypothalamic 
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hormones.1,2 
  In the pons, catecholamine neurons accumulate in the locus coeruleus.  
Neurons in this nucleus produce noradrenaline with practically all neurons in the locus 
coeruleus containing NM.  The locus coeruleus is involved in the activation of activity 
states, such as the sleep-wake cycle and the regulation of gathering and processing of 
sensory information during attentive state.  Pigmented neurons are scattered in clusters 
throughout the medial midbrain and continue into the arcuate nucleus of the 
hypothalamus.  Compared with other catecholamine cells, neurons in the substantia 
nigra consistently contain larger amounts of NM.  Although dopamine and 
noradrenaline synthesis are required for NM production, the synthesis and use of the 
catecholamines do not ensure that NM is produced. 1,2  
Comparison of Melanins 
 Peripheral melanins are diverse in proportion and amount of eumelanin to 
pheomelanin.  It is produced in melanocytes and either remains within the cell or is 
transferred to other cell types, such as keratinocytes or hair cells.  NM exists as dark 
colored granules in cytoplasm of catecholaminergic neurons where it is synthesized. 
NM in non-neuronal cells is associated with neurodegeneration after toxin-induced 
neuron death.  Although melanin and NM are found in the cytoplasm of their 
respective cells, the structure of NM appears very differently to that of peripheral 
melanins.1,2,3 In peripheral tissues, melanins are thought to function as endogenous 
mediators of oxidative mechanisms.  By analogy, NM may participate in a similar role 
within the brain.  It was suggested that synthesis of NM could play a protective role 
within the cell by preventing the accumulation of toxic catechol derivative by 
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incorporating into the polymer.  This could provide a chemoprotective mechanism by 
interacting with a variety of potentially damaging molecules, such as pesticides and 
toxic compounds.  Epidemiologic research has linked PD development to pesticide 
exposure, implicating NM in the etiology of neurodegeneration in this disease.  
Another suggested role for NM is in the binding of metals, particularly toxic cations 
such as iron, zinc, copper, manganese, chromium, cobalt, mercury, lead and cadmium. 
1,2,3 Neuromelanin is also known to bind neurotoxic compounds such as paraquat, 
chloropromasine, galoperidol, and imipramine potentially toxic for dopaminergic 
neurons.  NM most likely plays a physiological role in intraneuronal iron homeostasis, 
as it strongly binds iron due to similar iron-binding sites structure being analogous to 
ferritin.  Changes were seen in NM in the PD brain where significantly less iron is 
bound to NM than that seen in normal brains.  This suggests that changes in iron-
binding to NM result in increased levels of intraneuronal free iron and subsequent cell 
damage seen in PD.  Many characteristics of normal biology of NM remain to be 
clarified, particularly the regulation of NM synthesis and turnover.  For peripheral 
melanins, enzymatic synthesis and turnover is highly regulated. 1,2,3 
Neuromelanin Location and Structure 
Neuromelanin is found in the pre-synaptic terminal of dopamine neurons.  It is 
absent at birth and becomes detectable in the brain around age one.5 It increases in 
synthesis during adolescence and continues to do so throughout a person’s lifetime.  
As a result, aged brains have a darker appearance in these regions. Neuromelanin is 
most noticeable in the substantia nigra and locus coeruleus catecholamine neurons.  
NM is the major iron storage component in the substantia nigra.5,6 
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Neuromelanins are spontaneous occurring polymers structurally similar to 
peripheral melanins, although unlike neuromelanins, peripheral melanins are non-
spontaneous and enzymatically driven. Both types have the ability to chelate and 
neutralize transition metals, ions, and lipids for long periods of time.  Molecular 
structure of neuromelanin contains cysteine in its pheomelanin core, which is 
surrounded by a eumelanin without a cysteine component; however, it is not known 
exactly how the polymer is arranged.5,6   
The fact that neuromelanins are packaged into double bound membrane 
structures within cells of the substantia nigra and other neural tissues suggests a 
beneficial function to sustaining this storage.  Nicotine bound to synthetic 
neuromelanin created in a lab, while caffeine did not.7 The active component of 
tobacco, nicotine, has surprisingly demonstrated a protective effect against 
Parkinson’s disease in both humans and animal models.  The mechanism of this effect 
is unknown.  Protection is observed when nicotine is administered before, but not 
after, neural toxicity.  Caffeine is also neuroprotective against Parkinson’s disease.  
Toxic levels of 6-hydroxydopamine can damage the blood-brain barrier by increasing 
the permeability.  The protection caffeine provides is thought to be attributed to its 
ability to prevent the barrier from increasing in permeability.7 Additional studies plan 
to measure binding affinity of more relevant environmental elements with 
neuromelanin with the goal of predicting and preventing chemical exposure damage 
which may initiate the onset and progression of Parkinson’s disease.7 As we learn 
more about neuromelanin structure and function, it becomes more clear that 
neuromelanin is a key component in dopaminergic balance; therefore, having a direct 
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effect on neurodegeneration. 
Peripheral Melanin-Concentrating Hormone 
 Melanin-Concentrating Hormone (MCH) is a hypothalamic neuropeptide 
characterized with a role in physiologic function in arousal, mood, reproduction, and 
energy homeostasis.  It is also found to be produced in the zona incerta.  Ablation of 
functional MCH resulted in increased energy expenditure through increased metabolic 
rate, increased locomotor activity, or both.  MCH is expressed in the central nervous 
system and is found primarily in the rostral zona incerta/incerto-hypothalamic and 
lateral hypothalamic areas.  No strong physiological effects of circulating MCH have 
been discovered.  There appears to be some differential regulation of MCH levels 
between a combination of gender and adiposity.  Circulating MCH was not a marker 
of energy homeostasis and suggests that circulating MCH may not have a signaling 
role. 3,8    
 MCH binds to and activates MCH receptors found on the surface of plasma 
membranes.  The MCH1 receptors are additionally coupled to the Gi signaling 
pathway that inhibits cyclic adenosine monophosphate (cAMP) production and 
densely expressed in the nucleus accumbens (NAc) shell, locus coeruleus, and dorsal 
raphe nucleus.  The receptor mRNA and protein are distributed in the hypothalamic 
nuclei, paraventricular nucleus, hippocampal formation, septum, and amygdala.  All 
the aforementioned brain regions are implicated in the regulation of emotion and 
stress, as well as in learning and memory, suggesting that the MCH1 receptor is 
involved in these physiological events.  In contrast, MCH2 receptors are expressed 
specifically in the brain and detected in the hippocampus and amygdala.3,8 This could 
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indicate an involvement in food intake regulation and feeding behavior.  Transgenic 
mice overexpressing MCH in the lateral hypothalamus became mildly obese and 
susceptible to weight gain and insulin resistance when on a high fat diet.  MCH 
regulates secretion of adrenocorticotrophic hormone (ACTH), luteinizing releasing 
hormone, gonadotropins and thyroid stimulating hormone.  This indicates that MCH 
participates in the stress response, reproductive functions and energy homeostasis by 
regulating neuroendocrine systems. 3,8 
MCH in Depression and Anxiety: Behavioral and Neurochemical 
 MCH1 receptor is reportedly expressed strongly in the NAc shell, a region of 
the brain known for its role in motivation and reward.  Key elements of depressive 
states include decreased motivation and anhedonia.  Injection of a MCH1 receptor 
antagonist in forced swim test rats resulted in antidepressant effect.  This increases the 
possibility that the MCH system in the NAc shell is closely related to the development 
of depression.8 Further, MCH1 receptor deficiency in mice resulted in upregulation of 
dopamine receptors and noradrenaline transporters in the NAc shell, indicating that 
MCH1 receptors may mediate mesolimbic monoamine function.  Regulation of 
mesolimbic dopamines by the MCH system is thus considered to be involved in the 
development of depression.4 
 Hypothalamus-pituitary adrenal (HPA) axis dysfunction has been seen in 
patients with major depressive disorder, anorexia nervosa, and post-traumatic stress 
disorder.  MCH neurons project into the PVN of the hypothalamus, strongly 
implicating a HPA axis-related stress response.  MCH1 receptor mRNA and protein 
are abundant in this area.  Serotonergic transmission in the prefrontal cortex is 
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reported to be related to the modulation of anxiety and fear.8 Serotonin efflux 
increases in the prefrontal cortex in animals when exposed to conditioned fear stress.  
However, MCH1 receptor knockout mice have reduced basal extracellular serotonin 
levels in the prefrontal cortex.  Wild type mice used in the forced swim test had a 
marked increase in serotonin release in the prefrontal cortex, while this increase was 
blunted in MCH1 receptor null mice.  This suggests that disinhibition of serotonergic 
transmission by the MCH/MCH1 receptor signaling may lead to anxiety like 
behaviors.8 Additionally, an MCH1 receptor antagonist, chlordiazepoxide, has been 
reported to block the stress induced release of acetylcholine in the prefrontal cortex.  
As the prefrontal cortex is believed to be the area that regulates neuroendocrine 
responses to stress, this effect could therefore be involved in the anxiogenic effect 
mediated through the MCH1 receptors.  Knockout mice lacking MCH display 
antidepressant-like behavior (reduced immobility) in the forced swim test, also 
indicating that lack of MCH may cause depressive like behavior.  Efforts to delineate 
molecular mechanisms underlying antidepressant and anxiolytic effects of MCH1 
receptor antagonists have just begun, and these studies will provide a clearer picture to 
better understand the role of the MCH system and the molecular mechanisms of 
depression and anxiety.8 
Neurodegeneration and Neuromelanin 
 Neuromelanin binds iron and plays a protective and/or damaging role 
dependent upon the amount of bound iron present.  Dopamine oxidized by iron 
produces DA-o-quinone, which initiates neurodegenerative toxic pathways formed 
with amino acid residues.  Amino acid residues are made up of mainly cysteine 
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residues or different proteins.  On the other hand, cytosolic DA-o-quinone could react 
with cysteine to form cysteinyl-DA compounds, the precursor to neuromelanin 
synthesis.4 It is of interest to note that neuromelanin itself has a eumelanin component 
comprised of a cysteine core.  Neuromelanin accumulates in dopaminergic neurons of 
the substantia nigra throughout the aging process.  It appears that iron, dopamine, and 
neuromelanin interact through multiple pathways.  A common neurodegenerative 
disease marker is impairment of iron homeostasis, which is effected by several factors.  
These would include aging, mitochondrial dysfunction, oxidative stress, protein 
aggregation, etc.4 
 Increased accumulation of iron in specified brain regions, including the 
substantia nigra, is normal in aging; however, it is enhanced in many 
neurodegenerative disorders.  The age-related iron accumulation may be contributing 
to the neurodegenerative processes.  This is often associated with oxidative stress and 
cellular damage.  In neurodegenerative diseases, such as Parkinson’s, these same brain 
regions are less pigmented with much lower levels of neuromelanin.  The loss of 
substantia nigra neuromelanin is seen in all Parkinson’s patients.  The 
neurodegenerative process in Parkinson’s is initiated years before the appearance of 
motor symptoms become present.  One symptom of Parkinson’s includes depression.4 
The current scientific general consensus is that of multiple factor involvement 
resulting in the loss of neuromelanin dopaminergic neurons during Parkinson’s.  Some 
of which include neuroinflammation, oxidative stress, protein degradation 
dysfunction, endoplasmic reticulum stress, and mitochondrial dysfunction, to name a 
few.  It is important to remember that the formation of a-quinones by dopaminergic 
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oxidation occurs inside the neurons that are lost during the disease.  These a-quinones 
can participate in both neurotoxic and neuroprotective reactions.  It is most likely that 
cell death is induced by the a-quinones during dopaminergic oxidation and is a main 
event that explains why neurodegeneration is a very slow process in Parkinson’s.4   
 The synthesis of neuromelanin itself is a protective process which is sustained 
by excess dopamine in the cytosol and not accumulated by synaptic vesicles.  
Dopamine in the cytosol can be oxidized to create DA-o-quinone by iron mediated 
catalysts and then follow one of two different pathways: eumelanin or pheomelanin.  
Without neuromelanin synthesis, dopamine accumulation in the cytosol would induce 
the neurotoxic effects previously described.4 
 Neuromelanin possesses two types of iron binding sites.  In neurodegenerative 
conditions of iron overload, such as with Parkinson’s, the high affinity sites of 
neuromelanin would be saturated.  Iron would only be able to bind to low affinity 
sites.  If this were to occur, iron is bound into a low stability complex and would be 
easily released, becoming toxic by participating in redox processes and oxidizing 
ascorbate, a main antioxidant system in the brain.  Neuromelanin iron overload can 
also catalyze dopamine oxidation and formation of further DA-o-quinone, which 
induces oxidative modification of proteins, unleashing a neurodegenerative cascade.4 
 When neuromelanin iron overload is present, the rate of neuromelanin 
degradation by hydrogen peroxide increases as well.  This is likely to occur during 
microglia, when neuromelanin released by dying neurons is phagocytosed and broken 
down, so reactive iron and other toxins previously accumulated by neuromelanin are 
suddenly released and can cause cell death.  Neuromelanin likely contributes to 
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neurodegenerative progress by contributing to a neuroinflammatory process that 
involves activation of microglia.  Increased levels of redox-active iron have been 
reported in neuromelanin of the substantia nigra from Parkinson’s patients.4 A 
common feature of Parkinson’s is neuromelanin release from dying neurons in the 
extracellular space of the substantia nigra, along with increased microglial activity.  
Neuromelanin granules released into the extracellular space of the substantia nigra 
would most likely remain for long periods of time due to the level of granule 
insolubility.  The extra-neuronal neuromelanin granules would serve as a chronic 
source of neuronal inflammation.  A protective role of neuromelanin has been 
hypothesized when iron is bound under these physiological conditions, but a toxic 
effect of neuromelanin iron complexes occurs when iron overload is present in the 
brain.4 
 In the last thirty years there has been increasing evidence that dysregulation of 
cytosolic dopamine and reactive metals, particularly iron, plays an important role in 
the pathogenesis of Parkinson’s Disease.  Neuromelanin blocks reactive iron and 
forms stable complexes preventing iron toxicity.  When conditions are disturbed, iron 
and neuromelanin initiates a series of toxic neuroinflammatory steps that creates a 
‘vicious cycle’ sustaining the progression of the disease.4 
 It was recently suggested that neuromelanin plays the role of inducing alpha-
synuclein (a-syn) expression and accumulation, which is another way neuromelanin is 
suggested to regulate neurodegeneration in Parkinson’s.  Pathological neuron death 
induced by a-syn could occur through various mechanisms, including oxidative stress 
and preventing protein degradation.  What causes a-syn to convert from a non-toxic 
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protein into a toxic one is unclear.  Some causes for toxic a-syn accumulation may 
include missense mutations in the a-syn gene, higher concentration and 
posttranslational modification of a-syn.  Neuromelanin induces a-syn expression in the 
dopaminergic neurons of the substantia nigra in aged and Parkinson’s brain.9 
Neuromelanin binds directly with a-syn in lateral areas of the substantia nigra neurons 
in Parkinson’s patients.  Since a-syn is expressed in melanoma and nevus, but not in 
non-melanocytic cutaneous carcinoma and healthy skin, it would suggest that melanin 
may induce the expression of a-syn.  Also, a-syn mRNA expression was significantly 
higher in individual neuromelanin containing dopaminergic neurons in Parkinson’s 
patients than those of healthy controls.9 This finding further supports the claim of 
neuromelanin induced expression of a-syn.  Neuromelanin also increases the 
accumulation of a-syn in dopaminergic neurons.  The increased levels of a-syn 
increased the levels of neuromelanin in dopaminergic neurons, which suggests a-syn 
may promote the biosynthesis of neuromelanin in dopaminergic neurons.  A-syn plays 
a key role in the pathogenesis of Parkinson’s Disease.9 Although Parkinson’s is not 
commonly considered genetic, a missense mutation in the a-syn gene could cause 
early onset familial Parkinson’s.  Abnormal a-syn toxicity forms to dopaminergic 
neurons and normal function loss of the protein are important causes of the 
pathogenesis in sporadic Parkinson’s.  The study suggests that interaction between 
neuromelanin and a-syn is the mechanism for modulation of neuronal susceptibility.  
Increased a-syn in individual melanized neurons and its accumulation redistributed to 
neuromelanin in the substantia nigra early in Parkinson’s disease, but did not do so in 
healthy controls.  Alternatively, a-syn induces the biosynthesis of neuromelanin by 
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increasing the levels of cytosolic dopamine.  The conclusion of this particular study 
stated that neuromelanin is responsible for Parkinson’s disease and age-related 
increase of accumulated a-syn.9 
 It is of interest to note that 66% of Parkinson’s patients report having motor 
symptom onset on their right side first.  Almost all patients with Parkinson’s show 
both clinical and imaging asymmetry. Handedness may correlate with motor symptom 
asymmetry.10 The left hemisphere could very well have greater potential for 
neurodegeneration as well. However, the presence of imaging asymmetry in healthy 
controls suggests that neuromelanin lateralization may not be specific to Parkinson’s.  
It is unknown whether this is an innate occurrence, or if it is a consequence of the 
aging process.10 
One of the main differences between catecholamine neurons in some 
mammalian species is the presence or absence of neuromelanin in the cytoplasm.  This 
would be important to know for some comparative neurobiological studies, especially 
with the use of lab animals.  It is not known why neuromelanin is absent in some 
mammalian species.  Catecholamine neurons are separated into three different 
categories: dopaminergic, noradrenergic, and adrenergic.2 
 Neuromelanin is a result of catecholaminergic oxidation, including 
norepinephrine (noradrenaline) in the Locus Coeruleus. Neuromelanins also remove 
excess catecholamines from within a cell.  Imaging studies optimized to detect 
neuromelanin are showing greater signal in the Locus Coeruleus in older adults is 
associated with higher verbal knowledge.  Lower signal is associated with 
Alzheimer’s disease and minor cognitive impairment.11 
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 Animal studies are showing norepinephrine helps protect neurons from damage 
that can cause neurodegeneration with age, such as excitotoxicity and neuronal 
inflammation.  Introducing norepinephrine to the hippocampus of older rats reversed 
age-related long-term possible deficits.  The increase in norepinephrine improved 
cognition in the aging rats and in transgenic mice models of Alzheimer’s.  
Norepinephrine plays a key role in age-related cognitive ability and appears to effect 
attention and memory function as well.11 The Locus Coeruleus is the brains key source 
of norepinephrine.12 
 Brain and cognitive reserve reference an individual’s ability to manage 
cognitive decline or disease later in life.  The idea of cognitive reserve has created 
much interest in the field of aging, especially with Alzheimer’s.  Aspects believed to 
encourage reserve not only predict lower risk of dementia but also mask the severity 
of underlying neurodegenerative diseases.12 Cognitive reserve capacity is thought to 
be dependent upon physical neural resources and higher cognitive reserve scores.  
Scores are based on an individual’s level of education, occupation, and IQ.  
Neuromelanin signal intensity was associated with cognitive reserve, especially in 
those with higher verbal intelligence.  Elderly individuals with low levels of cognitive 
reserve showed greater association with locus coeruleus neuromelanin intensity levels 
and attentional shifting.12 This indicates that the integrity of the noradrenergic system 
supports cognitive flexibility. Neuromelanin signal in the Locus Coeruleus was much 
higher in older adults than younger adults and lower in women than in men.  These 
findings lend support to the idea that by enhancing the locus coeruleus norepinephrine 
system function and an individual’s enriching life experiences might help to protect 
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cognitive health later in life.12 
Neuromelanin and Mood Disorders 
 Iron is a co-factor of tyrosine hydroxylase, which converts tyrosine into 
dopamine and then later into norepinephrine.13 Dopamine regulates cellular iron 
homeostasis by increasing iron into macrophages and later promotes intracellular 
oxidative stress.  Other disorders this research may be of interest to not only includes 
neurodegenerative disorders but dopamine dysfunction disorders as well, such as 
restless legs syndrome.  Specifically, one may note the pathogenesis of these disorders 
or the efficacy of dopamine agonist therapy to overcome neuronal iron deficiency.13   
Dopamine dysfunction plays an important role in the pathogenesis of 
schizophrenia.14,15 Further research is being conducted specifically in the area of 
dopaminergic pathways and the substantia nigra.  Antipsychotic drugs currently used 
to treat schizophrenia function through blocking dopamine receptors.  Patients with 
Parkinson’s being treated with dopamine-enhancing compounds, such as levodopa, 
may experience psychotic episodes which mimic the symptoms of schizophrenia. The 
substantia nigra is a major origin of dopaminergic pathways.  Image studies have 
shown more dopamine is produced in the substantia nigra of schizophrenic patients.  
Increased levels of tyrosine hydroxylase were also detected, indicating increased 
levels of dopamine synthesis.  The Substantia nigra in schizophrenia is hyperactive, 
which is linked to the prefrontal cortex hypofunction of the disease.14  
 Increased levels of neuromelanin are being seen through MRI in the substantia 
nigra of schizophrenic patients.  This finding indicates the existence of increased 
levels of dopamine production in the substantia nigra.  Neuromelanin is now being 
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used as a signal or biomarker for researching dopaminergic and noradrenergic 
pathways in schizophrenia. Neuromelanin MRI imaging has the potential to be useful 
for schizophrenic diagnosis.15 
 The substantia nigra area of the brain plays an important role in reward and 
movement.  One study researching the link between neuromelanin levels in the 
substantia nigra and psychosis severity found higher levels of neuromelanin to be 
associated with increased severity of psychosis.  Schizophrenic psychosis is associated 
with dopamine dysfunction, characterized by increased levels of dopamine and 
dopamine synthesis.16 The use of neuromelanin MRI imaging allows more research to 
be conducted in disorders beyond those that are neurodegenerative.  The ability to 
measure neuromelanin concentrations and capture dopamine function in the substantia 
nigra will contribute to research in other areas.  Some such areas include looking to 
see if abnormalities in neuromelanin can be detected and assist in predicting if an 
individual is more likely to develop a psychotic disorder among those that already 
show early symptoms of psychosis.  Further exploration is also being conducted in 
whether neuromelanin MRI could be used to determine if an individual would best 
benefit from dopaminergic treatment.16 
 Tyrosine hydroxylase is the enzyme that limits the rate of norepinephrine 
production.  Norepinephrine promotes hypothalamic-pituitary-adrenal activity.  One 
study examined the levels of tyrosine hydroxylase in the locus coeruleus of mood 
disordered patients.  Higher locus coeruleus neuromelanin activity was seen in patients 
with suicidal depression, especially those with violent suicidal behaviors.17 Tyrosine 
hydroxylase was present in the cytoplasm and neuron fibers containing neuromelanin 
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in both controls and mood-disordered patients.  The locus coeruleus was found to be 
greatly activated in major depressive disorder patients but not in Bipolar disorder 
patients. There was no increase of tyrosine hydroxylase in Bipolar disorder patients.  
This would indicate a different type of locus coeruleus activity between these two 
subtypes of mood disorders.  Different stress-related molecular changes in the locus 
coeruleus contribute to the different clinical symptoms of major depressive disorder 
and bipolar disorder.  Dysfunction of the norepinephrine system supports the 
pathogenesis of mania-associated disorders.17 
Protective Role of Exercise on Stress System Dysregulation 
 Stress is defined as a reaction to various real or perceived stimuli that threatens 
to disrupt the homeostasis of the organism.  When under threat, the human body elicits 
a set of neuroendocrine responses that enables them to cope with the demands of 
homeostatic challenge.  This adaptation is mediated by activation of the stress system, 
which includes the HPA axis and the sympathetic nervous system (SNS).  This 
increases secretion of glucocorticoids (GC) and catecholamines respectively.  
Neuroendocrine response to stress is the mobilization of lipids from adipose tissue and 
glucose from the hepatic glycogen stores.18  Together with the development of an 
insulin resistant state in skeletal muscles ensures adequate energy supply to the brain, 
facilitating cognitive and physical adaptation for the “fight or flight” response.  This 
adaptation is a controlled deviation from homeostasis and has been termed allostasis, 
which means “maintaining stability through change.”  The immediate effects of 
allostasis are mostly protective for the organism, but in the long-term, overactivation 
is associated with the development of chronic disease or risk of mental illness.  
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Allostatic load is mainly determined by two factors, one being individual perception of 
a stressful situation or “mental fitness,” and two is the general physical condition of 
the individual or “physical fitness.”  Regular physical activity may have a protective 
effect on alleviating allostatic load and its health consequences.18,19 
 Today’s stressors are more likely to be psychological in nature, such as 
emotional, social, and professional, rather than physical.  The stress response to a 
psychological stressor is similar to the physical challenge response and includes 
activation of the HPA axis and the SNS.  However, psychological stress is different in 
that it does not require an increased metabolic demand and there is no clear beginning 
and end.  Chronic elevation of GC levels from persistent stress may have a negative 
effect on hippocampal structure and function, producing deficits in both memory and 
cognition.  Chronic stress produces deleterious effects on the brain, such as high levels 
of GC decrease the number of apical dendrite branch points and produce cell loss in 
the hippocampus. 18,19 Chronic stress decreases levels of brain derived neurotropic 
factor (BDNF) in the hippocampus of rodents.  BDNF regulates the survival and 
differentiation of neurons in the CNS and regulates synaptic plasticity.  Individuals 
suffering from posttraumatic stress disorder have shown to have hippocampal atrophy.  
The hippocampus is involved in memory function and is important for “context” 
memory, the times and places of events that are emotionally laden.  The hippocampus 
also regulates the stress response and inhibits the response of the HPA axis to stress.  
These neuronal structures are also involved in the control of the emotions and the 
stress response.  It is unknown if stress causes permanent alteration of these neural 
structures within the limbic system or if it leads to persistent stress reaction and 
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allostatic responses.18,19 
 Exercise is “the training of the body to improve its function and enhance its 
fitness.”  The benefits are derived from an indirect action of exercise through stress 
reduction as well as effect on various metabolic functions of the body.  Aside from the 
protective effects of exercise on physical and metabolic aspects related to stress, 
psychological and cognitive benefits have also been reported.  These benefits include 
improvements in depression and anxiety scores and general improvement in mood and 
cognitive function.  Results from detailed meta-analyses show that aerobic exercise is 
associated with reduction in anxiety scores, although the results were not uniform 
across the various outcome measures.18,19  Biological components may explain the 
beneficial effect on depression symptoms derived from research showing that exercise 
promotes the secretion of neurotransmitters, like serotonin and dopamine.  Regular 
exercise alleviates the depressive state and reduces urine cortisol amounts and 
epinephrine excretion.  These findings suggest that regular exercise has beneficial 
antidepressant and anxiolytic effects associated with decrease in the neuroendocrine 
response to stress.  In a study of over 32,000 people, it was discovered that less 
physically active individuals were twice as likely to report high stress levels while 
physically active individuals were less reactive to psychological stressors.  Although 
there was a dose-response effect between physical activity and psychological well-
being, the most prominent effect within the level of stress and dissatisfaction was seen 
between the group with low and moderate physical activity.18,19 
 With there being inconsistency between studies, the overall evidence strongly 
suggests that sensitivity to stress is reduced after exercise training.18,19,20  Factors that 
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modulate the degree of stress response include the duration of the stress exposure, 
perceived controllability of the stressor, and physiological state of the organism.  
Exercise may provide a way to control these factors and lead to adaptive effects on the 
HPA axis and SNS by lowering cortisol and catecholamine levels as well as reduced 
cardiovascular and SNS response to stressful stimuli.  Exercise also increases 
endogenous opioid activity in the CNS and peripheral nervous system, contributing to 
a stress buffering effect of euphoria, analgesia and mood improvement.  Physical 
activity produces CNS adaptations that prevent or ameliorate deleterious effects of 
chronic stress on mental and physical health. 18,19,20 
Exercise Down-regulation of MCH 
 As previously discussed, chronic stress is a risk factor for anxiety disorders.  
Chronic and repeated stress in animal models induces anxiety-like behaviors in 
various behavioral tests, lasting for up to three months after the stressor was removed.  
These studies in animal models revealed that neurotransmitters, including GABA, 
monoamines, cannabinoids, neuropeptides, neurotrophins, and cytokines regulate 
anxiety states.20  Repeated stress up-regulated MCH in the hippocampus, amygdala, 
and lateral hypothalamus, the areas important for emotional behaviors.20  Exercise 
downregulates the stress induced increase of MCH and affords long lasting anxiolytic 
effects.  It was speculated that corticosterone increases from stress stimuli induced the 
up regulation of MCH in the hippocampus.  When in vitro experiment of the HT22 
hippocampal cell line was treated with corticosterone, MCH expression increased 
significantly.  The corticosterone treated mice were then introduced to scheduled 
exercise to determine if the exercise would reverse the MCH upregulation in the 
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brain.20 MCH up-regulated expression in the hippocampus, basolateral amygdala and 
lateral hypothalamus were reversed in the animals exposed to the scheduled exercise 
treatment.  These changes in MCH expression are consistent with the idea that 
exercise, as a treatment for stress, has an opposing effect on anxiety-like behaviors.  
Corticosterone treatment induced MCH mRNA expression supports the possibility 
that up-regulation of MCH expression was initiated by corticosterone.  Finding that 
stress increased MCH expression, while exercise reversed the effect, supports the 
hypothesis that repeated stress produces anxiety-like behaviors by upregulating MCH 
in the brain while exercise counteracts stress-induced MCH expression and stress 
induced anxiety-like behaviors. 20  
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